Gastro-intestinal system recommendations
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
|
Updated 07/06/2022 |
Budesonide orodispersible for maintenance treatment of eosinophilic oesophagitis | Recommendation | Recommended as an option | 07/06/2022 |
| Infliximab biosimilars | See Musculoskeletal and joint diseases recommendations | Recommended as an option | 02/06/2015 | |
| Infliximab Subcutaneous (Remsima®) | Musculoskeletal and joint diseases recommendations | Recommended as an option during Covid-19 Pandemic. | 22/02/2022 | |
| Leukapheresis with Adacolumn™ for Inflammatory Bowel Disease (NETAG) | Recommendation | Not recommended | 18/01/2011 | |
|
Updated 31/01/2023 |
Transanal Irrigation Systems (TAIs) for neurogenic bowel dysfunction, chronic constipation, and chronic faecal incontinence | Recommended for restricted use. Recommended as per NTAG Decision Summary in NENC Medicines Committee Recommendations from December 2022 https://northeastnorthcumbria.nhs.uk/about-us/publications/medicines-committee/ | 15/11/2022 |